NCT00430170

Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.

Detailed description

Dipyridamole has been proven to reduce targeting of Annexin A5 in responses to ischemic exercise, indicating protection against ischemia-reperfusion injury in humans (pharmacological preconditioning). Dipyridamole increases the endogenous adenosine level by inhibition of the nucleoside transporter (ENT-1). Activation of the adenosine receptor protects against ischemia-reperfusion injury. We hypothesize that endogenous adenosine mediates the protective effect of dipyridamole against ischemia-reperfusion injury. Therefore the adenosine receptor antagonist caffeine will reduce the benefit of dipyridamole on forearm ischemia-reperfusion injury.

Conditions

• Cardiovascular Disease
• Ischemia-Reperfusion Injury

Interventions

Type	Name	Description
DRUG	Dipyridamole	Dipyridamole 2x200mg 7day per os
DRUG	caffeine	caffeine 4mg/kg iv

Timeline

• Start date: 2007-01-01
• Primary completion: 2007-03-01
• Completion: 2007-04-01
• First posted: 2007-02-01
• Last updated: 2008-07-29

Locations

1 site across 1 country: Netherlands